Key clinical point: Relative to younger peers, older women with HR-positive, HER2-negative advanced breast cancer derived similar benefit, but had greater toxicity, from addition of a CDK4/6 inhibitor to an AI.
Major finding: Patients aged ≥75 years had better progression-free survival if treated with a CDK4/6 inhibitor plus an AI as compared with an AI alone (hazard ratio for events, 0.49), a benefit similar to that among younger peers, but with more grade 3/4 adverse events (88.8% vs. 73.4%).
Study details: A pooled analysis of data from three first-line randomized controlled trials among 1,827 total postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer.
Disclosures: Dr. Singh disclosed no relevant conflicts of interest. The study did not receive any specific funding.